Återgå till huvudnavigering Återgå till sök Gå direkt till huvudinnehållet

In silico Analyses of Immune System Protein Interactome Network, Single-Cell RNA Sequencing of Human Tissues, and Artificial Neural Networks Reveal Potential Therapeutic Targets for Drug Repurposing Against COVID-19

  • Andres Lopez-Cortes
  • , Patricia Guevara-Ramirez
  • , Nikolaos C. Kyriakidis
  • , Carlos Barba-Ostria
  • , Angela Leon Caceres
  • , Santiago Guerrero
  • , Esteban Ortiz-Prado
  • , Cristian R. Munteanu
  • , Eduardo Tejera
  • , Domenica Cevallos-Robalino
  • , Ana Maria Gomez-Jaramillo
  • , Katherine Simbana-Rivera
  • , Adriana Granizo-Martinez
  • , Gabriela Perez-M
  • , Silvana Moreno
  • , Jennyfer M. Garcia-Cardenas
  • , Ana Karina Zambrano
  • , Yunierkis Perez-Castillo
  • , Alejandro Cabrera-Andrade
  • , Lourdes Puig San Andres
  • Carolina Proano-Castro, Jhommara Bautista, Andreina Quevedo, Nelson Varela, Luis Abel Quinones, Cesar Paz-y-Mino

Publikation: Bidrag till tidskriftArtikel i vetenskaplig tidskriftPeer review

Sammanfattning

Background: There is pressing urgency to identify therapeutic targets and drugs that allow treating COVID-19 patients effectively.Methods: We performed in silico analyses of immune system protein interactome network, single-cell RNA sequencing of human tissues, and artificial neural networks to reveal potential therapeutic targets for drug repurposing against COVID-19.Results: We screened 1,584 high-confidence immune system proteins in ACE2 and TMPRSS2 co-expressing cells, finding 25 potential therapeutic targets significantly overexpressed in nasal goblet secretory cells, lung type II pneumocytes, and ileal absorptive enterocytes of patients with several immunopathologies. Then, we performed fully connected deep neural networks to find the best multitask classification model to predict the activity of 10,672 drugs, obtaining several approved drugs, compounds under investigation, and experimental compounds with the highest area under the receiver operating characteristics.Conclusion: After being effectively analyzed in clinical trials, these drugs can be considered for treatment of severe COVID-19 patients. Scripts can be downloaded at.
OriginalspråkEngelska
Artikelnummer598925
Antal sidor24
TidskriftFrontiers in Pharmacology
Volym12
DOI
StatusPublicerad - 2021

Nyckelord

  • COVID-19
  • immune system
  • single-cell RNA sequencing
  • artificial neural networks
  • drug repurposing

Citera det här